In February 2025, the FDA formally declared the semaglutide drug shortage resolved — a decision that set off a cascading enforcement timeline affecting millions of patients who had been obtaining compounded semaglutide from pharmacies at a fraction of the branded drug cost.
This article explains exactly what the FDA declared, the enforcement dates that followed, and the current regulatory status of compounded semaglutide entering 2026.
What Is a Drug Shortage and Why Did Semaglutide Qualify?
Under Section 506E of the Federal Food, Drug, and Cosmetic Act, the FDA maintains a drug shortage list when a medication is in 'inadequate supply.' From 2022 through early 2025, the explosive demand for semaglutide (Wegovy for weight loss, Ozempic for diabetes) far outpaced Novo Nordisk's manufacturing capacity.
When a branded drug is in shortage, the FDA exercises enforcement discretion over compounding pharmacies — allowing 503A (retail) and 503B (outsourcing facility) pharmacies to produce copies even when those copies would ordinarily infringe the branded drug's regulatory protections.
The February 2025 Shortage Resolution
On February 21, 2025, the FDA updated its shortage database to reflect that semaglutide injection — including all doses of Wegovy (2.4 mg) and Ozempic — was no longer in shortage. Novo Nordisk had expanded manufacturing and supply chains had normalized.
This single database update triggered a legally mandated enforcement clock.
The Enforcement Timeline
- February 21, 2025: FDA removes semaglutide from the shortage list
- March 19, 2025: 503B outsourcing facilities must cease producing bulk compounded semaglutide
- May 22, 2025: 503A retail compounding pharmacies must cease producing patient-specific compounded semaglutide
- After May 22, 2025: FDA begins active enforcement — warning letters, injunctions, and seizures for non-compliant pharmacies
What Changed for Patients
Patients who had been paying $100–$300/month for compounded semaglutide faced an abrupt transition back to branded pricing — Wegovy lists at approximately $1,350/month without insurance. GoodRx and manufacturer savings programs (Novo Nordisk's NovoCare) provide some relief, but access gaps remain.
Notably, the shortage resolution did not affect tirzepatide (Mounjaro, Zepbound). As of early 2026, tirzepatide remains on the FDA shortage list, meaning compounded tirzepatide continues to be available from 503A and 503B pharmacies in the near term.
Legal Challenges and Current Status
Multiple compounding pharmacy trade groups filed legal challenges to the FDA's shortage determination, arguing the supply data was incomplete. As of mid-2025, courts had not issued injunctions blocking enforcement. FDA warning letters to non-compliant pharmacies began arriving in June 2025.
Patients seeking lower-cost options should consult their prescribers about manufacturer programs, insurance coverage appeals, or tirzepatide as an alternative (which remains compoundable while the shortage persists).